Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing therapies for autoimmune diseases and cancer, with a pipeline spanning clinical and preclinical programs. Its lead immunology candidates are CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus,… From the company’s description.
In fiscal 2025, Cullinan Therapeutics, Inc. reported a net loss of $219.88M. Operations used $175.75M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cullinan Therapeutics, Inc. does
In the company’s own words
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing therapies for autoimmune diseases and cancer, with a pipeline spanning clinical and preclinical programs. Its lead immunology candidates are CLN-978, a CD19xCD3 bispecific T cell engager being studied in systemic lupus erythematosus, rheumatoid arthritis and Sjögren’s disease, and velinotamig, a BCMAxCD3 engager licensed for development outside Greater China. In oncology, CLN-049 is a FLT3xCD3 engager in clinical development for acute myeloid leukemia and myelodysplastic syndrome. The company also collaborates with Taiho Pharmaceutical on zipalertinib, an oral EGFR inhibitor for non-small cell lung cancer with EGFR exon 20 insertion mutations; Taiho is responsible for commercialization. Cullinan’s programs focus on T cell-engaging therapies, while zipalertinib provides a partnered small-molecule program. The company has no commercial products described among these programs and relies on third parties for much of its development and manufacturing work.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1789972
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cullinan Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cullinan Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cullinan Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cullinan Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cullinan Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”